Abstract 1535
Background
EGFR mutation is the major driver mutation in East Asian lung cancer. By and large, this group of lung cancer patients has a better prognosis in advanced stage pulmonary adenocarcinoma. However, the prognostic role of these sensitizing EGFR mutations in early stage is uncertain. We aimed to investigate the prognostic value of EGFR mutation and other factors for tumor recurrence in completely resected LNNPA.
Methods
We recruited 220 patients with LNNPA who were diagnosed and treated at the King Chulalongkorn Memorial Hospital from January 1, 2009 to December 31, 2016. Recurrence included pathological diagnosis, imaging confirmations, or death. Recurrence-free survival was analyzed by univariable and multivariable Cox regression analyses.
Results
Median follow up time was 4 (2.7-5.6) years. There were more female (62%), never smokers (68%), stage I (86%) and EGFR mutations (54%). The most common EGFR mutations were exon 19 deletion (51%) and L858R (43%). Most patients did not receive adjuvant treatment (85.6%). There were 60 out of 220 (27.3%) patients had recurrent disease. The median time to recurrence was 2.3 years. The rate of loco-regional, distant and both types of recurrence were 27%, 68% and 5% respectively. Univariate analysis revealed smoking ≥ 10 pack-year, performance status ≥ 2, tumor size ≥ 4 cm, histologic grade ≥ 2, lymphovascular invasion, visceral pleural invasion, tumor necrosis and bronchial resection margin (BRM) < 2 cm were significant prognostic factors for tumor recurrence. However, tumor size ≥ 4 cm, visceral pleural invasion, tumor necrosis and BRM < 2 cm remained the significant prognostic factors with multivariate analysis (Table). Sensitizing EGFR mutation was not a significant prognostic factor in this cohort by both univariate and multivariate analyses.Table: 1451P
Multivariate analysis
Covariate | HR | 95% CI | P-value |
---|---|---|---|
Tumor size ≥ 4 cm | 1.96 | 1.1 - 3.6 | 0.03 |
Visceral Pleural invasion | 2.38 | 1.3 - 4.3 | 0.004 |
< 2 cm of bronchial resection margin | 2.48 | 1.4 - 4.3 | 0.002 |
Tumor necrosis | 3.12 | 1.7 - 5.6 | < 0.001 |
EGFR mutation | 1.23 | 0.6 - 2.7 | 0.57 |
Conclusions
Among Thai, East Asian, early stage lung cancer, sensitizing EGFR mutation has similar outcomes to those without EGFR mutation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Ratchadapisek Sompoch Endowment Fund.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3909 - Spectrum of pathogenic germline mutations in Chinese lung cancer patients through next-generation sequencing
Presenter: Ying Huang
Session: Poster Display session 1
Resources:
Abstract
3061 - Poor prognostic impact of NTRK2 gene variation in Esophageal Squamous Cell Carcinoma
Presenter: Ye Chen
Session: Poster Display session 1
Resources:
Abstract
4735 - Mutation profile of Tibetan lung cancer revealed by Whole Exome Sequencing
Presenter: Xin Wang
Session: Poster Display session 1
Resources:
Abstract
5236 - Synergistic activity between niraparib and chemotherapy in colorectal cancer: molecular determinants from a preclinical model
Presenter: Pietro Paolo Vitiello
Session: Poster Display session 1
Resources:
Abstract
4051 - cRGDfK (cRGD) conjugated Pyropheophor¬bide-a (Pyro), a new tumor photodynamic agent, is highly accumulated and specific in tumor cell killing
Presenter: Fengwei Wang
Session: Poster Display session 1
Resources:
Abstract
859 - The expression of MMR, CD133 and the presence of p53 wt predict the response to Cabazitaxel in malignant neural tumors cell lines.
Presenter: Kevin Doello
Session: Poster Display session 1
Resources:
Abstract
2497 - IKS01, a next generation antibody drug conjugate (ADC) designed to be efficacious in tumors with low and moderate levels of folate receptor expression
Presenter: Jenny Thirlway
Session: Poster Display session 1
Resources:
Abstract
1636 - Novel Non-Camptothecin Compounds with Antiproliferative Activities against Breast Cancer Cells
Presenter: Wen-shan Li
Session: Poster Display session 1
Resources:
Abstract
3443 - Sensitization of estrogen receptor-positive breast cancer cells to tamoxifen by novel epi-oligomycin A
Presenter: Margarita Yastrebova
Session: Poster Display session 1
Resources:
Abstract
840 - Autophagy inhibition enhances leflunomide-induced cytotoxicity in human bladder cancer cells
Presenter: Li Cheng
Session: Poster Display session 1
Resources:
Abstract